Zentiva erweitert sein Angebot im Bereich Biologika mit der EU-weiten Einführung seines ersten Biosimilars

Core Insights - Zentiva has announced the EU-wide launch of its first monoclonal antibody biosimilar, marking its strategic entry into the biosimilars market and enhancing patient access to high-quality biological medicines across Europe [2][3]. Group 1: Company Strategy - The launch signifies a significant step for Zentiva into the biological medicines sector, aligning with its mission to make high-quality treatments more accessible and affordable for patients in Europe [3]. - This move is part of a broader strategic growth plan aimed at diversifying the company's product offerings beyond traditional generics, as biological medicines increasingly represent a larger share of healthcare expenditures in Europe [4]. Group 2: Market Position - The introduction of the biosimilar positions Zentiva as a reliable partner in healthcare, committed to facilitating access to essential therapies [2][3]. - The biosimilar, approved through the centralized procedure of the European Medicines Agency (EMA), will gradually become available in European markets starting in December [3]. Group 3: Company Overview - Zentiva focuses on the development, manufacturing, and delivery of high-quality, affordable medications for over 100 million people in more than 30 countries in Europe and beyond [5]. - The company operates four production sites and has a broad network of external manufacturing partners to ensure supply security, employing over 5,000 individuals dedicated to patient health [5].